Literature DB >> 25257886

Diagnostic and management dilemma of a pancreas-kidney transplant recipient with aplastic anaemia.

Andrea Viecelli1, Hannah Hessamodini1, Bradley Augustson2, Wai Hon Lim1.   

Abstract

We report a case of a 57-year-old woman with type I diabetes who had received a simultaneous pancreas-kidney (SPK) transplant maintained on tacrolimus, mycophenolic acid (MPA) and prednisolone. Her renal allograft failed 6 years post-transplant but she continued to have a normal functioning pancreatic allograft. Over the course of 5 years, she developed progressive bone marrow failure with repeat bone marrow aspirates demonstrating an evolution from erythroid hypoplasia to hypocellular marrow and eventual aplastic anaemia despite discontinuation of MPA and reduction of tacrolimus. She was transfusion-dependent and had frequent admissions for sepsis. Despite treatment with antithymocyte globulin and cyclosporine for aplastic anaemia, she developed fatal invasive pulmonary aspergillosis within 3 weeks of treatment. Even though the cause of aplastic anaemia is likely multifactorial, this case highlights the difficulty in balancing the need for versus the risk of ongoing immunosuppression in a SPK transplant recipient who continues to have normal pancreatic graft function. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25257886      PMCID: PMC4180581          DOI: 10.1136/bcr-2014-205076

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  8 in total

Review 1.  Current concepts in the pathophysiology and treatment of aplastic anemia.

Authors:  Neal S Young
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

2.  Horse versus rabbit antithymocyte globulin in acquired aplastic anemia.

Authors:  Phillip Scheinberg; Olga Nunez; Barbara Weinstein; Priscila Scheinberg; Angélique Biancotto; Colin O Wu; Neal S Young
Journal:  N Engl J Med       Date:  2011-08-04       Impact factor: 91.245

3.  High-dose cyclophosphamide compared with antithymocyte globulin for treatment of acquired severe aplastic anemia.

Authors:  Fengkui Zhang; Li Zhang; Liping Jing; Kang Zhou; Huijun Wang; Guangxin Peng; Yang Li; Yuan Li; Jianping Li; Lei Ye; Lihui Shi; Huihui Fan; Xin Zhao; Yulin Chu; Yushu Hao; Jianxiang Wang
Journal:  Exp Hematol       Date:  2013-01-09       Impact factor: 3.084

4.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

Review 5.  How I treat hemophagocytic lymphohistiocytosis.

Authors:  Michael B Jordan; Carl E Allen; Sheila Weitzman; Alexandra H Filipovich; Kenneth L McClain
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

6.  A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment.

Authors:  P J Martin; G Schoch; L Fisher; V Byers; C Anasetti; F R Appelbaum; P G Beatty; K Doney; G B McDonald; J E Sanders
Journal:  Blood       Date:  1990-10-15       Impact factor: 22.113

Review 7.  Graft-versus-host disease.

Authors:  James L M Ferrara; John E Levine; Pavan Reddy; Ernst Holler
Journal:  Lancet       Date:  2009-03-11       Impact factor: 79.321

Review 8.  Post-liver-transplant anemia: etiology and management.

Authors:  Anurag Maheshwari; Rajnish Mishra; Paul J Thuluvath
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.